Apr
Industry 4.0 Masterclass
Leading authority on strategy and competitiveness
Henrik is named by Financial Times as one of the leading authority on strategy and competitiveness. One of the most influential business thinkers, who has set the agenda for nations and the fortune 100 companies.
He is notorious for his personal involvement to define the core differentiating, competitive aspects and to identify how to innovate and where to transform.
Originator of the Industry 4.0 and Digital themes today
Henrik is best known as the originator of the “4th Industrial Revolution” (Industry 4.0) and the mastermind of the European Digital Revolution (German Digital Agenda), which ignited the global themes of today. As the inaugurator of Germany’s digital agenda in 09, he ignited a global wave of national and corporate digital strategy adoptions.
MEDIA PARTNERS
Feb
Industry 4.0 Masterclass
Leading authority on strategy and competitiveness
Henrik is named by Financial Times as one of the leading authority on strategy and competitiveness. One of the most influential business thinkers, who has set the agenda for nations and the fortune 100 companies.
He is notorious for his personal involvement to define the core differentiating, competitive aspects and to identify how to innovate and where to transform.
Originator of the Industry 4.0 and Digital themes today
Henrik is best known as the originator of the “4th Industrial Revolution” (Industry 4.0) and the mastermind of the European Digital Revolution (German Digital Agenda), which ignited the global themes of today. As the inaugurator of Germany’s digital agenda in 09, he ignited a global wave of national and corporate digital strategy adoptions.
MEDIA PARTNERS
May
2ND ANNUAL CDx & PERSONALIZED MEDICINE SUMMIT
[Sassy_Social_Share]
2ND ANNUAL CDx & PERSONALIZED MEDICINE SUMMIT
The summit ensures maximum knowledge transfer among professionals and decision makers to exchange and elaborate on the best practices within the companion diagnostics (CDx) industry. More importantly, partnership opportunities and commercializing CDx tests with pharmaceutical and biotech companies will be explored.
KEY TOPICS
WHY YOU SHOULD BE THERE ?
- Novel Diagnostic Technologies
- Strategic Partnerships for CDx – Challenges and Opportunities
- Partnering strategies to achieve successful commercialization of CDx
- Future key areas for the Development of Personalized Medicine
- Partnering to Deliver Personalized Medicine
- Finding the appropriate business models for CDx companies
- Development of new Business Models for the Healthcare Industry
- The role of complementary diagnostics in targeted therapy selection
- Regulatory Update on Companion Diagnostics
- Emerging investment trends and opportunities
- Regulatory and Commercial Considerations
2. Learn about the latest technologies and most pressing topics specific to your business.
3. Discuss about new opportunities for your products and services with key decision makers.
4. Get new tips, tactics and implement the latest innovations.
5. Get an overview on innovative emerging technologies and business partnership opportunities.
6. Interact and connect with leading companies and their representatives.
MEDIA PARTNERS
REQUEST FORM
Nov
2nd Annual Cancer Immunotherapy Summit
2ND ANNUAL CANCER IMMUNOTHERAPY SUMMIT
[su_note note_color=”#66c4ff” radius=”5″]In this summit, the most successful and promising new cancer treatment strategies will be explored. This summit is one of the most important opportunities, where you will explore the best practices in cancer immunotherapy. It is particularly important for the fields key opinion leaders, most exciting newcomers and others to come together to discuss and learn about the up-to-the-minute trends.[/su_note]
[su_note note_color=”#66c4ff” radius=”5″]The summit ensures maximum knowledge transfer among professionals and decision makers to exchange and elaborate on the best practices and explore business partnership opportunities. This premier B2B summit is one of the few opportunities, where you will meet face to face with leading industry professionals and decision makers and discuss your business potential and opportunities. It will also enable the participants to learn about the most advanced techniques and tools through which they can assess their portfolios and development potential.[/su_note]
KEY TOPICS
EU and US Regulatory aspects
Management of side effects
What’s new in specific cancer types – News in specific cancer types
The true potential of the next generation immune checkpoint pathways
Resistance to therapy
Patient selection and predictive biomarkers
Advancements in T-cell engineering
Commercialization of Viable T-cell therapies
Revolutionary cancer treatment with personalised cancer vaccines
Combining immune checkpoint inhibitors with chemotherapy or radiotherapy and beyond
Technological developments
Preclinical and clinical progress in Cancer Immunotherapy
Advanced methods, technological developments and strategies in Cancer Immunotherapy
Imaging and nuclear medicine and design of immuno-oncology trials
Progressive genetic engineering techniques
WHY YOU SHOULD BE HERE?
Network with business development and licensing professionals as well as professionals in your sector
Implement the latest innovations
Learn about the latest technologies and most pressing topics specific to your business
Get an overview on innovative emerging technologies and promote business partnerships within the sector
Interact and connect with leading professionals
Discuss about new opportunities for your products and services with key decision makers
FEATURED SPEAKERS
Ivan Diaz-Padilla, MD, PhD
Louis Boon
Dr. John Maher
Dr. Marek Štastný, PhD.
Stefanos Theoharis
Larissa S. Carnevalli, PhD
Madalin Sevestrian
Ronald Kurt Kuoch
FEATURED COMPANIES
MEDIA PARTNERS
REQUEST FORM
Feb
INTERNATIONAL BIOSIMILARS SUMMIT
INTERNATIONAL BIOSIMILARS SUMMIT
[su_note note_color=”#66c4ff” radius=”5″]The biosimilars industry landscape is rapidly evolving and creating significant revenue opportunities for companies that can successfully develop and market them. According to the GBI research global biosimilars market value could hit $55 billion by 2020 from its current value of $20 billion, which clearly shows the industries trending business opportunities. Thus, this summit is one of the most important opportunities, where you will explore your business potential in this trending industry. It is particularly important for the fields key opinion leaders, most exciting new-comers and others to come together to discuss and learn about the up-to-the-minute trends of biosimilars, commercial strategy, effective planning and strategies for biosimilars future development, etc. It will bring together experts from all levels of the value chain to analyze and tackle the latest and greatest opportunities in the biosimilars industry. The summit ensures maximum knowledge transfer among professionals and decision makers to exchange and elaborate on the best practices and explore business partnership opportunities.[/su_note]
KEY TOPICS
EU, US and international regulatory aspects
The use of innovative bio-analytics
Risk management Stratgies for biosimilars
From biosimilars to biogenerics
Numeracy and the Understanding of Clinical Trials with Biosimilars
Biosimilars regulatory affairs
Emerging investment trends and opportunities
Combination products and self-injection devices for biosimilars: Opportunities and pitfalls
Opportunities and pitfall in medical communication for biosimilar products
What can we learn from real life data?
Challenges of Biosimilar Labeling
Establishing “Finger-print Like” Biosimilarity – Critical Characterization Steps for Biosimilar Assessment
Biosimilar insulin, regulatory profile and challenges for gaining marketing authorization approval
Are you on track? – Rapidly evolving regulatory landscape for the development of Biosimilars
The Future of Biosimilars Testing and Development
WHY YOU SHOULD BE HERE?
Network with business development and licensing professionals as well as professionals in your sector
Implement the latest innovations
Learn about the latest technologies and most pressing topics specific to your business
Get an overview on innovative emerging technologies and promote business partnerships within the sector
Interact and connect with leading professionals
Discuss about new opportunities for your products and services with key decision makers
FEATURED SPEAKERS
Cecil Nick
Fiona M Greer BSc (Hons) MSc PhD
Dr. Jakob Lange, Ph.D.
Dr. Steinar Madsen
Uwe Gudat
Fredrik Sundberg
Grzegorz Orlik, MD
Christian Maasch
Chantal LE FLOCH
FEATURED COMPANIES
SPONSOR
MEDIA PARTNERS
REQUEST FORM
Feb
GLOBAL CDx & PERSONALIZED MEDICINE SUMMIT
GLOBAL CDx & PERSONALIZED MEDICINE SUMMIT
Personalized medicine will change the way medicine is practiced. The new therapies will benefit both patients and physicians in many ways. Patients will experience fewer side effects and physicians will be armed with more precise tools and medicine. Companion diagnostic co-development has the potential to significantly alter the drug development process and commercialization of drug candidates by yielding safer drugs with enhanced therapeutic efficacy in a faster, more cost-effective manner. This premier B2B summit will bring together experts from all levels of the value chain to analyze and tackle the latest and greatest opportunities in the CDx.
The summit ensures maximum knowledge transfer among professionals and decision makers to exchange and elaborate on the best practices within the companion diagnostics (CDx) industry. More importantly, partnership opportunities and commercializing CDx tests with pharmaceutical and biotech companies will be explored.
KEY TOPICS
WHY YOU SHOULD BE THERE ?
- Novel Diagnostic Technologies
- Strategic Partnerships for CDx – Challenges and Opportunities
- Partnering strategies to achieve successful commercialization of CDx
- Implementation of a Personalized Medicine program
- Emerging approach to precision medicine strategy
- Partnering to Deliver Personalized Medicine
- Finding the appropriate business models for CDx companies
- The role of complementary diagnostics in targeted therapy selection
- The laboratory developed test (LDT) & In vitro diagnostic (IVD) Models
- Liquid biopsy methodologies for non-invasive diagnostic development
- Next generation sequencing protocols
- Regulatory Update on Companion Diagnostics
2. Learn about the latest technologies and most pressing topics specific to your business.
3. Discuss about new opportunities for your products and services with key decision makers.
4. Get new tips, tactics and implement the latest innovations.
5. Get an overview on innovative emerging technologies and business partnership opportunities.
6. Interact and connect with leading companies and their representatives.
FEATURED SPEAKERS
Edward Abrahams, Ph.D.
Dr. Reinhard Ortmann
Paul Docherty
Dr. Annette O. Walter
Susanne Munksted
Robert Hewitt, MB BS, PhD
SPONSORS
FEATURED COMPANIES
MEDIA PARTNERS
REQUEST FORM
Feb
WORLD BIOBANKING SUMMIT
WORLD BIOBANKING SUMMIT
[su_note note_color=”#66c4ff” radius=”5″]The global biobanking market was USD 142 million in 2011 and it is forecasted that this market will reach USD 216.3 million in 2018 with the compound annual growth rate of 5.4 % from 2011 – 2018. Moreover, the biobanking market witnessed an increased trend of mergers and acquisitions among vendors. This summit will address the latest developments in biobanking from its discovery to commercialization. It is one of the most important opportunities, where you will explore your business potential in biobanking. The U.S and Europe have the largest market size in biobanks. However, the rapid growth in population in Asia Pacific countries will affect the market of the developed countries. This summit will bring together experts from all levels of the value chain to analyze and tackle the latest and greatest opportunities in biobanking. The summit ensures maximum knowledge transfer among professionals and decision makers to exchange and elaborate on the best practices and explore business partnership opportunities.[/su_note]
KEY TOPICS
Quality management system in biobanking
Latest technological developments in biobanking
Strategic Partnerships for Biobanking – Challenges and Opportunities
Biobanking In Emerging Markets – Regulatory and Commercial Considerations
Biostatistics and data management
Cloud-Based Sample Management
Biobanking discovery to commercialization
Automated biobanking
Biobanks in clinical and translational research
WHY YOU SHOULD BE HERE?
Network with business development and licensing professionals as well as professionals in your sector
Implement the latest innovations
Learn about the latest technologies and most pressing topics specific to your business
Meet with experts and influencers in your industry face to face
Get an overview on innovative emerging technologies and explore your business potential
Interact and connect with leading companies and their representatives
Discuss about new opportunities for your products and services with key decision makers
Get new tips, tactics and implement the latest innovations
FEATURED SPEAKERS
Mag. Dr. Helmuth Haslacher, BSc BA
Peadar Mac Gabhann
Dr. Balwir Matharoo-Ball
Dr. Rita T. Lawlor, PhD
Paul Lomax
Robert Hewitt, MB BS, PhD
Dr. Dejun Tang
Prof. Jens K. Habermann, M.D., Ph.D.
Isabel Gil Aldea, MD, PhD
Mark Divers, PhD
